ICIs act as antibodies against immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1), thereby restoring the ability of immune cells to kill tumor cells. This evidence concerns the gene PDCD1 and neoplasm.